The motion sickness treatment market size valued for $393.70 million in 2021 and is estimated to reach $525.03 million by 2031, exhibiting a CAGR of 2.9% from 2022 to 2031. Motion sickness, also known as travel sickness or kinetosis, is a condition characterized by a set of symptoms that occur when a person is exposed to motion or movement. It occurs when there is a discrepancy between the sensory information that the eyes, inner ear, and body provide to the brain. The brain receives conflicting information from the eyes and inner ear about the movement and orientation of the body, and this can cause a variety of symptoms such as nausea, vomiting, dizziness, headaches, sweating, and fatigue. It can be caused by various forms of motion, including car rides, airplane flights, boat rides, or even virtual reality experiences.
Motion sickness is more likely to occur in people more prone to it, such as children, pregnant women, and people with a history of migraines. Treatment for motion sickness may include over-the-counter and prescription medications which includes antihistamines, anticholinergics and other medications. The products are available in branded as well as generic form and can be easily accessed through retail and other pharmacies.Major factors that drive the growth of the motion sickness treatment market include increase in incidences of motion sickness, and rise in awareness among the people regarding motion sickness and its treatment options.
In addition, increase in number of travelers is also a major factor contributing toward the market growth. For instance, the World Tourism Organization (UNWTO) stated that more than 900 million tourists travelled internationally in 2022 which was double the number recorded in 2021. This shows a significant increase in the number of travelers, both domestically and internationally. In addition, an article, Motion Sickness: Manifestations and Prevention published by Defence Food Research Laboratory, Mysore stated that, about 5 to 10% of travelers are highly susceptible to motion sickness, while others are moderately susceptible. Thus, it highlights huge incidences of motion sickness among the travelers around the globe, which furthers propels the growth of the motion sickness treatment market.
In addition, major key players are focusing on developing new drugs and APIs that are highly potent and efficient in reducing the symptoms of motion sickness. Moreover, there is an increase in outsourcing research activities by the pharmaceutical companies to private contract research organizations (CROs), which allows the company to stay competitive and flexible in a world of increasingly advanced technologies. This supports the key market players to develop novel drug and medications for motion sickness prevention and treatment, which further propels the growth of the market.
On the other hand, lack of awareness about motion sickness and its available treatment in some underdeveloped countries hinder the growth of the market. In addition, some people may be hesitant to use medication to treat motion sickness due to concerns about side effects or a preference for natural remedies. This is projected to limit the demand for motion sickness medications. Moreover, the presence of alternate solutions, such as wearable, for motion sickness may indeed be a hindrance to the market growth. Wearable devices, such as acupressure bands, wristbands, and headsets, have become increasingly popular in recent years as non-pharmaceutical alternatives for managing motion sickness. These factors limit the growth of the market.
However, emerging economies of Asia-Pacific and LAMEA present lucrative opportunities for market players for investments. These regions are characterized by large populations with high levels of economic growth and increasing disposable incomes. As a result, there is a growing demand for healthcare services, raising awareness for motion sickness treatment medication. Moreover, governments in these regions are increasingly investing in healthcare infrastructure and expanding access to healthcare services, which is further anticipated to augment the market growth.
The motion sickness treatment market is segmented into drug class, route of administration, distribution channel and region. By drugs class, the market is categorized into antihistamines, anticholinergics and others. By route of administration, the market is bifurcated into oral, and others. By distribution channel, the market is segregated into hospital pharmacies, drug stores & retail pharmacies and online pharmacies. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
Major key players that operate in the motion sickness treatment market include Prestige Consumer Healthcare Inc., Baxter International Inc., Novartis AG, WellSpring Pharmaceutical Corporation., Amneal Pharmaceuticals LLC., Abbott Laboratories, Sun Pharmaceutical Industries Ltd., Viatris Inc., Zydus Cadila and Teva Pharmaceutical Industries Limited.
Motion sickness is more likely to occur in people more prone to it, such as children, pregnant women, and people with a history of migraines. Treatment for motion sickness may include over-the-counter and prescription medications which includes antihistamines, anticholinergics and other medications. The products are available in branded as well as generic form and can be easily accessed through retail and other pharmacies.Major factors that drive the growth of the motion sickness treatment market include increase in incidences of motion sickness, and rise in awareness among the people regarding motion sickness and its treatment options.
In addition, increase in number of travelers is also a major factor contributing toward the market growth. For instance, the World Tourism Organization (UNWTO) stated that more than 900 million tourists travelled internationally in 2022 which was double the number recorded in 2021. This shows a significant increase in the number of travelers, both domestically and internationally. In addition, an article, Motion Sickness: Manifestations and Prevention published by Defence Food Research Laboratory, Mysore stated that, about 5 to 10% of travelers are highly susceptible to motion sickness, while others are moderately susceptible. Thus, it highlights huge incidences of motion sickness among the travelers around the globe, which furthers propels the growth of the motion sickness treatment market.
In addition, major key players are focusing on developing new drugs and APIs that are highly potent and efficient in reducing the symptoms of motion sickness. Moreover, there is an increase in outsourcing research activities by the pharmaceutical companies to private contract research organizations (CROs), which allows the company to stay competitive and flexible in a world of increasingly advanced technologies. This supports the key market players to develop novel drug and medications for motion sickness prevention and treatment, which further propels the growth of the market.
On the other hand, lack of awareness about motion sickness and its available treatment in some underdeveloped countries hinder the growth of the market. In addition, some people may be hesitant to use medication to treat motion sickness due to concerns about side effects or a preference for natural remedies. This is projected to limit the demand for motion sickness medications. Moreover, the presence of alternate solutions, such as wearable, for motion sickness may indeed be a hindrance to the market growth. Wearable devices, such as acupressure bands, wristbands, and headsets, have become increasingly popular in recent years as non-pharmaceutical alternatives for managing motion sickness. These factors limit the growth of the market.
However, emerging economies of Asia-Pacific and LAMEA present lucrative opportunities for market players for investments. These regions are characterized by large populations with high levels of economic growth and increasing disposable incomes. As a result, there is a growing demand for healthcare services, raising awareness for motion sickness treatment medication. Moreover, governments in these regions are increasingly investing in healthcare infrastructure and expanding access to healthcare services, which is further anticipated to augment the market growth.
The motion sickness treatment market is segmented into drug class, route of administration, distribution channel and region. By drugs class, the market is categorized into antihistamines, anticholinergics and others. By route of administration, the market is bifurcated into oral, and others. By distribution channel, the market is segregated into hospital pharmacies, drug stores & retail pharmacies and online pharmacies. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
Major key players that operate in the motion sickness treatment market include Prestige Consumer Healthcare Inc., Baxter International Inc., Novartis AG, WellSpring Pharmaceutical Corporation., Amneal Pharmaceuticals LLC., Abbott Laboratories, Sun Pharmaceutical Industries Ltd., Viatris Inc., Zydus Cadila and Teva Pharmaceutical Industries Limited.
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the motion sickness treatment market analysis from 2021 to 2031 to identify the prevailing motion sickness treatment market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the motion sickness treatment market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global motion sickness treatment market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Drug Class
- Antihistamines
- Anticholinergics
- Others
By Route of Administration
- Oral
- Others
By Distribution Channel
- Drug Store and Retail Pharmacies
- Online Pharmacies
- Hospital Pharmacies
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
Key Market Players
- Sun Pharmaceutical Industries Ltd.
- Viatris Inc.
- Teva Pharmaceutical Industries Limited
- Prestige Consumer Healthcare Inc.
- Baxter International Inc.
- Novartis AG
- Amneal Pharmaceuticals LLC
- Abbott Laboratories
- WellSpring Pharmaceutical Corporation
- Zydus Lifesciences Limited
Please note:
- Online Access price format is valid for 60 days access. Printing is not enabled.
- PDF Single and Enterprise price formats enable printing.
Table of Contents
CHAPTER 1: INTRODUCTION
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET OVERVIEW
CHAPTER 4: MOTION SICKNESS TREATMENT MARKET, BY DRUG CLASS
CHAPTER 5: MOTION SICKNESS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
CHAPTER 6: MOTION SICKNESS TREATMENT MARKET, BY DISTRIBUTION CHANNEL
CHAPTER 7: MOTION SICKNESS TREATMENT MARKET, BY REGION
CHAPTER 8: COMPETITIVE LANDSCAPE
CHAPTER 9: COMPANY PROFILES
List of Tables
List of Figures
Companies Mentioned
- Sun Pharmaceutical Industries Ltd.
- Viatris Inc.
- Teva Pharmaceutical Industries Limited
- Prestige Consumer Healthcare Inc.
- Baxter International Inc.
- Novartis AG
- Amneal Pharmaceuticals LLC
- Abbott Laboratories
- WellSpring Pharmaceutical Corporation
- Zydus Lifesciences Limited
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
